Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
Humans
Rilpivirine
/ therapeutic use
HIV-1
/ genetics
Anti-HIV Agents
/ pharmacology
HIV Infections
Botswana
/ epidemiology
Nitriles
/ pharmacology
Pyrimidines
/ pharmacology
Genotype
Drug Resistance, Viral
/ genetics
Anti-Retroviral Agents
/ therapeutic use
HIV Seropositivity
/ drug therapy
Mutation
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
received:
14
06
2023
accepted:
02
08
2023
medline:
4
10
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Pre-existing rilpivirine resistance-associated mutations (RVP-RAMs) have been found to predict HIV-1 virological failure in those switching to long-acting injectable cabotegravir/rilpivirine. We here evaluated the prevalence of archived RPV-RAMs in a cohort of people living with HIV (PWH). We analysed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs, which were defined according to the 2022 IAS-USA drug resistance mutation list and Stanford HIV drug resistance database. RPV-RAMs were identified in 757/5805 sequences, giving a prevalence of 13.0% (95% CI 12%-13.9%). Amongst the ART-naive group, 137/1281 (10.7%, 95% CI 9.1%-12.5%) had at least one RPV-RAM. Of the 4524 PWH with viral suppression on ART (VL <400 copies/mL), 620 (13.7%, 95% CI 12.7%-14.7%) had at least one RPV-RAM. E138A was the most prevalent RPV-RAM in the ART-naive group (7.9%) and the ART-suppressed group (9.3%). The rest of the mutations observed (L100I, K101E, E138G, E138K, E138Q, Y181C, H221Y, M230L, A98G, V179D, G190A, G190E and M230I) were below a prevalence of 1%. RPV-RAMs were present in 10.7% of ART-naive and 13.7% of ART-suppressed PWH in Botswana. The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.
Identifiants
pubmed: 37585352
pii: 7243234
doi: 10.1093/jac/dkad258
pmc: PMC10545497
doi:
Substances chimiques
Rilpivirine
FI96A8X663
Anti-HIV Agents
0
cabotegravir
HMH0132Z1Q
Nitriles
0
Pyrimidines
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2489-2495Subventions
Organisme : FIC NIH HHS
ID : K43 TW012350
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG006941
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Lancet HIV. 2022 Jun;9(6):e374-e375
pubmed: 35358419
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
AIDS Rev. 2012 Oct-Dec;14(4):268-78
pubmed: 23258301
AIDS. 2018 Jul 17;32(11):1543-1546
pubmed: 29762166
Elife. 2021 Jun 01;10:
pubmed: 34061023
Nucleic Acids Res. 2014 Oct;42(18):e144
pubmed: 25120265
Antivir Ther. 2016;21(5):405-12
pubmed: 26761642
Lancet. 2021 Dec 19;396(10267):1994-2005
pubmed: 33308425
Am J Health Syst Pharm. 2012 May 15;69(10):857-61
pubmed: 22555080
J Med Chem. 2007 May 17;50(10):2301-9
pubmed: 17441703
AIDS. 2023 May 1;37(6):1009-1011
pubmed: 36779485
J Mol Biol. 2004 Feb 20;336(3):569-78
pubmed: 15095972
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506
pubmed: 33136751
J Biol Chem. 1997 Jul 11;272(28):17581-7
pubmed: 9211905
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
N Engl J Med. 2020 Mar 19;382(12):1124-1135
pubmed: 32130806
Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S549-S556
pubmed: 36410377
J Med Chem. 2010 May 27;53(10):4295-9
pubmed: 20438081
Clin Infect Dis. 2013 Oct;57(7):1051-5
pubmed: 23797286
N Engl J Med. 2020 Mar 19;382(12):1112-1123
pubmed: 32130809
J AIDS Clin Res. 2012 Feb;3(2):141-147
pubmed: 23019537
J Int AIDS Soc. 2016 Apr 27;19(1):20683
pubmed: 27125320
J Antimicrob Chemother. 2015 Feb;70(2):562-5
pubmed: 25344807
J Antimicrob Chemother. 2014 Jan;69(1):12-20
pubmed: 23934770
Curr Opin HIV AIDS. 2022 Jan 1;17(1):22-31
pubmed: 34871188
Top Antivir Med. 2022 Oct-Nov;30(4):559-574
pubmed: 36375130
Clin Infect Dis. 2023 May 3;76(9):1646-1654
pubmed: 36660819
AIDS Res Hum Retroviruses. 2018 Aug;34(8):667-671
pubmed: 29732907
AIDS. 2021 Jul 15;35(9):1333-1342
pubmed: 33730748
AIDS. 2019 May 1;33(6):1073-1082
pubmed: 30946161
Curr Opin Virol. 2013 Apr;3(2):119-28
pubmed: 23602470
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26
pubmed: 24525469
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):18-22
pubmed: 21637112
AIDS Res Hum Retroviruses. 2016 May;32(5):427-33
pubmed: 26651266
Bioinformatics. 2000 Apr;16(4):400-1
pubmed: 10869039
PLoS One. 2017 Jul 28;12(7):e0181357
pubmed: 28753637
Enferm Infecc Microbiol Clin. 2015 Aug-Sep;33(7):498-9
pubmed: 25639908
PLoS One. 2015 Jan 30;10(1):e0117430
pubmed: 25635815
J Virol. 2003 Jan;77(2):1512-23
pubmed: 12502865
AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):835-8
pubmed: 12201905
J Biol Chem. 2012 Nov 2;287(45):38110-23
pubmed: 22955279
Antiviral Res. 2014 Jul;107:31-4
pubmed: 24746459
AIDS. 2011 May 15;25(8):1123-6
pubmed: 21505320
AIDS. 2017 Jan 2;31(1):61-70
pubmed: 27677163
Infect Genet Evol. 2013 Oct;19:337-48
pubmed: 23660484